Arvinas

Arvinas is a biopharmaceutical company focused on the discovery and development of novel therapies targeting protein-protein interactions (PPIs). Founded in 2014, the company is headquartered in Boston, Massachusetts, with additional research and development operations in Cambridge, Massachusetts, and San Diego, California. Arvinas employs a proprietary platform called ARV-110, which leverages small-molecule technology to modulate PPIs, a previously undruggable class of targets.

The company’s approach aims to address diseases with significant unmet medical needs, particularly in oncology and rare genetic disorders. One of its lead programs involves the development of a potential treatment for prostate cancer, utilizing a targeted protein degradation mechanism. This technology, known as PROTACs (Proteolysis-Targeting Chimeras), enables the selective degradation of disease-causing proteins within cells, offering a novel therapeutic strategy.

Arvinas has secured partnerships with major pharmaceutical companies, including Pfizer and Eli Lilly, to advance its pipeline. The company has also received funding from investors and government grants to support its research efforts. In addition to its core focus on oncology, Arvinas explores applications in neurodegenerative diseases and metabolic disorders.

The company’s mission is to develop transformative medicines that improve patient outcomes by targeting previously inaccessible biological pathways. Arvinas operates under a leadership team with expertise in drug discovery, biochemistry, and clinical development, aiming to bring innovative therapies to market efficiently. As of recent developments, the company continues to expand its clinical trials and collaborate with academic institutions to accelerate its scientific advancements.